Please login to the form below
ViraTherapeutics
This page shows the latest ViraTherapeutics news and features for those working in and with pharma, biotech and healthcare.
Boehringer links up with Trutino for cancer R&D
That includes the takeover of oncolytic virus specialist ViraTherapeutics at the end of 2018, which is focused on the latter’s lead candidate VSV-GP, a cancer therapy that works by
Latest news
-
Transgene slumps as viral cancer therapy fails phase 3 trial
Boehringer Ingelheim made a big play in the category when it bought ViraTherapeutics for $236m last September, as did Merck with its $394m purchase of Viralytics, while Abbvie and Johnson &Johnson
-
Boehringer taps Korea’s Bridge for Ofev follow-up
Last year, Boehringer also acquired the oncolytic virus specialist ViraTherapeutics for 210m and licensed a checkpoint inhibitor from OSE Immunotherapeutics in a deal valued at up to 1bn.
-
Boehringer bolts on another immuno-oncology company
Acquires ViraTherapeutics in a 210m takeover deal. Boehringer Ingelheim’s shopping spree in immuno-oncology has continued with a 210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working ... The privately-held German
-
Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal
by ViraTherapeutics in 2016.
-
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal
Boehringer Ingelheim has boosted its position in immuno-oncology by licensing an oncolytic virus therapy developed by Austrian biotech ViraTherapeutics. ... The deal also gives Boehringer an option to acquire ViraTherapeutics outright once phase I
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.
-
Deal Watch September 2016
With a headline value of $235m Boehringer Ingelheim entered into a collaboration with ViraTherapeutics to develop an oncolytic virus therapy platform. ... Boehringer also secured the option to acquire ViraTherapeutics after development of VSV-GP.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
